Literature DB >> 30515642

Toward 19F magnetic resonance thermometry: spin-lattice and spin-spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T.

Christian Prinz1, Paula Ramos Delgado1, Thomas Wilhelm Eigentler1, Ludger Starke1, Thoralf Niendorf1,2, Sonia Waiczies3.   

Abstract

OBJECTIVE: This study examines the influence of the environmental factor temperature on the 19F NMR characteristics of fluorinated compounds in phantom studies and in tissue.
MATERIALS AND METHODS: 19F MR mapping and MR spectroscopy techniques were used to characterize the 19F NMR characteristics of perfluoro-crown ether (PFCE), isoflurane, teriflunomide, and flupentixol. T1 and T2 mapping were performed, while temperature in the samples was changed (T = 20-60 °C) and monitored using fiber optic measurements. In tissue, T1 of PFCE nanoparticles was determined at physiological temperatures and compared with the T1-measured at room temperature.
RESULTS: Studies on PFCE, isoflurane, teriflunomide, and flupentixol showed a relationship between temperature and their physicochemical characteristics, namely, chemical shift, T1 and T2. T1 of PFCE nanoparticles was higher at physiological body temperatures compared to room temperature. DISCUSSION: The impact of temperature on the 19F NMR parameters of fluorinated compounds demonstrated in this study not only opens a trajectory toward 19F MR-based thermometry, but also indicates the need for adapting MR sequence parameters according to environmental changes such as temperature. This will be an absolute requirement for detecting fluorinated compounds by 19F MR techniques in vivo.

Entities:  

Keywords:  19F MR; Fluorine MR; Magnetic resonance; Spin–lattice relaxation; Thermometry

Mesh:

Substances:

Year:  2018        PMID: 30515642     DOI: 10.1007/s10334-018-0722-8

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


  26 in total

1.  Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.

Authors:  Franck Desmoulin; Véronique Gilard; Myriam Malet-Martino; Robert Martino
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

2.  In vivo imaging platform for tracking immunotherapeutic cells.

Authors:  Eric T Ahrens; Rafael Flores; Hongyan Xu; Penelope A Morel
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

3.  Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.

Authors:  N R Bolo; Y Hodé; J F Nédélec; E Lainé; G Wagner; J P Macher
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

4.  Fluorine (19F) MRS and MRI in biomedicine.

Authors:  Jesús Ruiz-Cabello; Brad P Barnett; Paul A Bottomley; Jeff W M Bulte
Journal:  NMR Biomed       Date:  2010-09-15       Impact factor: 4.044

5.  Perfluorocarbon temperature measurements using 19F NMR.

Authors:  B A Berkowitz; J T Handa; C A Wilson
Journal:  NMR Biomed       Date:  1992 Mar-Apr       Impact factor: 4.044

6.  Quantitative (19)F imaging of nmol-level F-nucleotides/-sides from 5-FU with T(2) mapping in mice at 9.4T.

Authors:  Yoshihiro Doi; Toshiyuki Shimmura; Hideto Kuribayashi; Yoshitsugu Tanaka; Yoko Kanazawa
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668

7.  Fluorine-19 fast recovery fast spin echo imaging for mapping 5-fluorouracil.

Authors:  Shigehiro Morikawa; Toshiro Inubushi; Masahito Morita; Koichiro Murakami; Chiaki Masuda; Jun-ichi Maki; Ikuo Tooyama
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

Review 8.  Fluorine magnetic resonance in vivo: a powerful tool in the study of drug distribution and metabolism.

Authors:  David G Reid; Philip S Murphy
Journal:  Drug Discov Today       Date:  2008-03-11       Impact factor: 7.851

9.  Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study.

Authors:  C N Karson; J E Newton; P Mohanakrishnan; J Sprigg; R A Komoroski
Journal:  Psychiatry Res       Date:  1992-08       Impact factor: 3.222

10.  19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.

Authors:  Greg O Cron; Nelson Beghein; Réginald Ansiaux; Philippe Martinive; Olivier Feron; Bernard Gallez
Journal:  Magn Reson Med       Date:  2008-01       Impact factor: 4.668

View more
  4 in total

1.  Special issue on fluorine-19 magnetic resonance: technical solutions, research promises and frontier applications.

Authors:  Sonia Waiczies; Mangala Srinivas; Ulrich Flögel; Philipp Boehm-Sturm; Thoralf Niendorf
Journal:  MAGMA       Date:  2019-02       Impact factor: 2.310

Review 2.  Nanotechnology as a Versatile Tool for 19F-MRI Agent's Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles.

Authors:  Joice Maria Joseph; Maria Rosa Gigliobianco; Bita Mahdavi Firouzabadi; Roberta Censi; Piera Di Martino
Journal:  Pharmaceutics       Date:  2022-02-09       Impact factor: 6.321

3.  In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy.

Authors:  Christian Prinz; Ludger Starke; Jason M Millward; Ariane Fillmer; Paula Ramos Delgado; Helmar Waiczies; Andreas Pohlmann; Michael Rothe; Marc Nazaré; Friedemann Paul; Thoralf Niendorf; Sonia Waiczies
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

4.  Pentafluorosulfanyl (SF5) as a Superior 19F Magnetic Resonance Reporter Group: Signal Detection and Biological Activity of Teriflunomide Derivatives.

Authors:  Christian Prinz; Ludger Starke; Tizian-Frank Ramspoth; Janis Kerkering; Vera Martos Riaño; Jérôme Paul; Martin Neuenschwander; Andreas Oder; Silke Radetzki; Siegfried Adelhoefer; Paula Ramos Delgado; Mariya Aravina; Jason M Millward; Ariane Fillmer; Friedemann Paul; Volker Siffrin; Jens-Peter von Kries; Thoralf Niendorf; Marc Nazaré; Sonia Waiczies
Journal:  ACS Sens       Date:  2021-10-19       Impact factor: 7.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.